Advertisement

Current Diabetes Reports

, Volume 9, Issue 6, pp 423–431 | Cite as

Not all neuropathy in diabetes is of diabetic etiology: Differential diagnosis of diabetic neuropathy

  • Roy FreemanEmail author
Article

Abstract

Diabetic peripheral neuropathy is the most common peripheral neuropathy in the developed world; however, not all patients with diabetes and peripheral nerve disease have a peripheral neuropathy caused by diabetes. Several (although not all) studies have drawn attention to the presence of other potential causes of a neuropathy in individuals with diabetes; 10% to 50% of individuals with diabetes may have an additional potential cause of a peripheral neuropathy and some may have more than one cause. Neurotoxic medications, alcohol abuse, vitamin B12 deficiency, renal disease, chronic inflammatory demyelinating neuropathy, inherited neuropathy, and vasculitis are the most common additional potential causes of a peripheral neuropathy in these series. The most common disorders in the differential diagnosis of a generalized diabetic peripheral neuropathy are discussed in this article. Prospective studies to investigate the prevalence of other disorders that might be responsible for a peripheral neuropathy in individuals with diabetes are warranted.

Keywords

Neuropathy Celiac Disease Peripheral Neuropathy Amyloidosis Autonomic Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dyck PJ, Kratz KM, Karnes JL, et al.: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817–824. (Published erratum appears in Neurology 1993, 43:2345.)PubMedGoogle Scholar
  2. 2.
    Gorson KC, Ropper AH: Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry 2006, 77:354–358.CrossRefPubMedGoogle Scholar
  3. 3.
    Lozeron P, Nahum L, Lacroix C, et al.: Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol 2002, 249:569–575.CrossRefPubMedGoogle Scholar
  4. 4.
    Straub RH, Rokitzki L, Schumacher T, et al.: [Patients with type-II diabetes mellitus and neuropathy have no deficiency of vitamins A, E, beta-carotene, B1, B2, B6, B12 and folic acid]. Med Klin (Munich) 1993, 88:453–457.Google Scholar
  5. 5.
    Rosenberg NR, Portegies P, de Visser M, Vermeulen M: Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatry 2001, 71:205–209.CrossRefPubMedGoogle Scholar
  6. 6.
    Boulton AJ, Vinik AI, Arezzo JC, et al.: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956–962.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnson RH, Robinson BJ: Mortality in alcoholics with autonomic neuropathy. J Neurol Neurosurg Psychiatry 1988, 51:476–480.CrossRefPubMedGoogle Scholar
  8. 8.
    Koike H, Mori K, Misu K, et al.: Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology 2001, 56:1727–1732.PubMedGoogle Scholar
  9. 9.
    Koike H, Iijima M, Sugiura M, et al.: Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol 2003, 54:19–29.CrossRefPubMedGoogle Scholar
  10. 10.
    Bolton CF, McKeown MJ, Chen R, et al.: Subacute uremic and diabetic polyneuropathy. Muscle Nerve 1997, 20:59–64.CrossRefPubMedGoogle Scholar
  11. 11.
    Krishnan AV, Kiernan MC: Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007, 35:273–290.CrossRefPubMedGoogle Scholar
  12. 12.
    Ropper AH: Accelerated neuropathy of renal failure. Arch Neurol 1993, 50:536–539.PubMedGoogle Scholar
  13. 13.
    Yosipovitch G, Yarnitsky D, Mermelstein V, et al.: Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve 1995, 18:768–771.CrossRefPubMedGoogle Scholar
  14. 14.
    Krishnan AV, Phoon RK, Pussell BA, et al.: Altered motor nerve excitability in end-stage kidney disease. Brain 2005, 128:2164–2174.CrossRefPubMedGoogle Scholar
  15. 15.
    London Z, Albers JW: Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin 2007, 25:257–276.CrossRefPubMedGoogle Scholar
  16. 16.
    Pastore C, Izura V, Marhuenda D, et al.: Partial conduction blocks in N-hexane neuropathy. Muscle Nerve 2002, 26:132–135.CrossRefPubMedGoogle Scholar
  17. 17.
    Korobkin R, Asbury AK, Sumner AJ, Nielsen SL: Gluesniffing neuropathy. Arch Neurol 1975, 32:158–162.PubMedGoogle Scholar
  18. 18.
    Deng H, He F, Zhang S, et al.: Quantitative measurements of vibration threshold in healthy adults and acrylamide workers. Int Arch Occup Environ Health 1993, 65:53–56.CrossRefPubMedGoogle Scholar
  19. 19.
    Post EJ, McLeod JG: Acrylamide autonomic neuropathy in the cat. Part 1. Neurophysiological and histological studies. J Neurol Sci 1977, 33:353–374.CrossRefPubMedGoogle Scholar
  20. 20.
    Windebank AJ, Grisold W: Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13:27–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Umapathi T, Chaudhry V: Toxic neuropathy. Curr Opin Neurol 2005, 18:574–580.CrossRefPubMedGoogle Scholar
  22. 22.
    Peltier AC, Russell JW: Advances in understanding druginduced neuropathies. Drug Saf 2006, 29:23–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Ropper AH, Gorson KC: Neuropathies associated with paraproteinemia. N Engl J Med 1998, 338:1601–1607.CrossRefPubMedGoogle Scholar
  24. 24.
    Ramchandren S, Lewis RA: Monoclonal gammopathy and neuropathy. Curr Opin Neurol 2009, 22:480–485.CrossRefPubMedGoogle Scholar
  25. 25.
    Vital A: Paraproteinemic neuropathies. Brain Pathol 2001, 11:399–407.PubMedCrossRefGoogle Scholar
  26. 26.
    Hadden RD, Nobile-Orazio E, Sommer C, et al.: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006, 13:809–818.CrossRefPubMedGoogle Scholar
  27. 27.
    Kyle RA, Therneau TM, Rajkumar SV, et al.: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362–1369.CrossRefPubMedGoogle Scholar
  28. 28.
    Eurelings M, Lokhorst HM, Kalmijn S, et al.: Malignant transformation in polyneuropathy associated with monoclonal gammopathy. Neurology 2005, 64:2079–2084.CrossRefPubMedGoogle Scholar
  29. 29.
    Sanchorawala V: Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006, 1:1331–1341.CrossRefPubMedGoogle Scholar
  30. 30.
    Falk RH, Skinner M: The systemic amyloidoses: an overview. Adv Intern Med 2000, 45:107–137.PubMedGoogle Scholar
  31. 31.
    Rajkumar SV, Gertz MA, Kyle RA: Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998, 104:232–237.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang AK, Fealey RD, Gehrking TL, Low PA: Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc 2008, 83:1226–1230.CrossRefPubMedGoogle Scholar
  33. 33.
    Skinner M, Anderson J, Simms R, et al.: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996, 100:290–298.CrossRefPubMedGoogle Scholar
  34. 34.
    Kyle RA, Gertz MA, Greipp PR, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336:1202–1207.CrossRefPubMedGoogle Scholar
  35. 35.
    Bryce AH, Kyle RA, Dispenzieri A, Gertz MA: Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 2006, 81:511–518.CrossRefPubMedGoogle Scholar
  36. 36.
    Ammendola A, Sampaolo S, Migliaresi S, et al.: Autonomic neuropathy in mixed cryoglobulinemia. J Neurol 2007, 254:215–219.CrossRefPubMedGoogle Scholar
  37. 37.
    Ammendola A, Sampaolo S, Ambrosone L, et al.: Peripheral neuropathy in hepatitis-related mixed cryoglobulinemia: electrophysiologic follow-up study. Muscle Nerve 2005, 31:382–385.CrossRefPubMedGoogle Scholar
  38. 38.
    Kumar N: Nutritional neuropathies. Neurol Clin 2007, 25:209–255.CrossRefPubMedGoogle Scholar
  39. 39.
    Healton EB, Savage DG, Brust JCM, et al.: Neurologic aspects of cobalamin deficiency. Medicine 1991, 70:229–245.CrossRefPubMedGoogle Scholar
  40. 40.
    Koffman BM, Greenfield LJ, Ali II, Pirzada NA: Neurologic complications after surgery for obesity. Muscle Nerve 2006, 33:166–176.CrossRefPubMedGoogle Scholar
  41. 41.
    Albin RL, Albers JW, Greenberg HS, et al.: Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 1987, 37:1729–1732.PubMedGoogle Scholar
  42. 42.
    Gonzalez-Duarte A, Robinson-Papp J, Simpson DM: Diagnosis and management of HIV-associated neuropathy. Neurol Clin 2008, 26:821–832.CrossRefPubMedGoogle Scholar
  43. 43.
    Simpson DM, Kitch D, Evans SR, et al.: HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006, 66:1679–1687.CrossRefPubMedGoogle Scholar
  44. 44.
    Schifitto G, McDermott MP, McArthur JC, et al.: Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005, 64:842–848.PubMedGoogle Scholar
  45. 45.
    Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005, 352:1343–1356.CrossRefPubMedGoogle Scholar
  46. 46.
    Koski CL, Baumgarten M, Magder LS, et al.: Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2009, 277:1–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Sharma KR, Cross J, Ayyar DR, et al.: Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002, 59:751–757.CrossRefPubMedGoogle Scholar
  48. 48.
    Haq RU, Pendlebury WW, Fries TJ, Tandan R: Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve 2003, 27:465–470.CrossRefPubMedGoogle Scholar
  49. 49.
    Laughlin RS, Dyck PJ, Melton LJ 3rd, et al.: Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009, 73:39–45.CrossRefPubMedGoogle Scholar
  50. 50.
    Reilly MM: Sorting out the inherited neuropathies. Pract Neurol 2007, 7:93–105.PubMedGoogle Scholar
  51. 51.
    Pareyson D: Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Neurol Sci 2004, 25:72–82.CrossRefPubMedGoogle Scholar
  52. 52.
    Rotthier A, Baets J, Vriendt ED, et al.: Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain 2009 Aug 3 (Epub ahead of print).Google Scholar
  53. 53.
    Auer-Grumbach M, Mauko B, Auer-Grumbach P, Pieber TR: Molecular genetics of hereditary sensory neuropathies. Neuromolecular Med 2006, 8:147–158.CrossRefPubMedGoogle Scholar
  54. 54.
    Shy ME, Garbern JY, Kamholz J: Hereditary motor and sensory neuropathies: a biological perspective. Lancet Neurol 2002, 1:110–118.CrossRefPubMedGoogle Scholar
  55. 55.
    Sheth S, Francies K, Siskind CE, et al.: Diabetes mellitus exacerbates motor and sensory impairment in CMT1A. J Peripher Nerv Syst 2008, 13:299–304.CrossRefPubMedGoogle Scholar
  56. 56.
    Bennett CL, Lawson VH, Brickell KL, et al.: Late-onset hereditary axonal neuropathies. Neurology 2008, 71:14–20.CrossRefPubMedGoogle Scholar
  57. 57.
    Berghoff C, Berghoff M, Leal A, et al.: Late onset autosomal dominant Charcot-Marie-Tooth 2 neuropathy in a Costa Rican family. Neurol Res 2009, 31:283–288.CrossRefPubMedGoogle Scholar
  58. 58.
    Chance PF: Inherited focal, episodic neuropathies: hereditary neuropathy with liability to pressure palsies and hereditary neuralgic amyotrophy. Neuromolecular Med 2006, 8:159–174.CrossRefPubMedGoogle Scholar
  59. 59.
    Axelrod FB: Hereditary sensory and autonomic neuropathies. Familial dysautonomia and other HSANs. Clin Auton Res 2002, 12(Suppl 1):I2–I14.CrossRefPubMedGoogle Scholar
  60. 60.
    Bejaoui K, Wu C, Scheffler MD, et al.: SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 2001, 27:261–262.CrossRefPubMedGoogle Scholar
  61. 61.
    Dawkins JL, Hulme DJ, Brahmbhatt SB, et al.: Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 2001, 27:309–312.CrossRefPubMedGoogle Scholar
  62. 62.
    Ando Y, Nakamura M, Araki S: Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005, 62:1057–1062.CrossRefPubMedGoogle Scholar
  63. 63.
    Adams D: Hereditary and acquired amyloid neuropathies. J Neurol 2001, 248:647–657.CrossRefPubMedGoogle Scholar
  64. 64.
    Plante-Bordeneuve V, Ferreira A, Lalu T, et al.: Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007, 69:693–698.CrossRefPubMedGoogle Scholar
  65. 65.
    Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses. N Engl J Med 1997, 337:898–909.CrossRefPubMedGoogle Scholar
  66. 66.
    Dalmau J, Graus F, Rosenblum MK, Posner JB: Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992, 71:59–72.CrossRefPubMedGoogle Scholar
  67. 67.
    Graus F, Keime-Guibert F, Rene R, et al.: Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138–1148.CrossRefPubMedGoogle Scholar
  68. 68.
    Lucchinetti CF, Kimmel DW, Lennon VA: Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998, 50:652–657.PubMedGoogle Scholar
  69. 69.
    Vernino S, Lennon VA: New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000, 47:297–305.CrossRefPubMedGoogle Scholar
  70. 70.
    Yu Z, Kryzer TJ, Griesmann GE, et al.: CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49:146–154.CrossRefPubMedGoogle Scholar
  71. 71.
    Lacomis D, Giuliani MJ, Steen V, Powell HC: Small fiber neuropathy and vasculitis. Arthritis Rheum 1997, 40:1173–1177.CrossRefPubMedGoogle Scholar
  72. 72.
    Goransson LG, Tjensvoll AB, Herigstad A, et al.: Small-diameter nerve fiber neuropathy in systemic lupus erythematosus. Arch Neurol 2006, 63:401–404.CrossRefPubMedGoogle Scholar
  73. 73.
    Omdal R, Mellgren SI, Goransson L, et al.: Small nerve fiber involvement in systemic lupus erythematosus: a controlled study. Arthritis Rheum 2002, 46:1228–1232.CrossRefPubMedGoogle Scholar
  74. 74.
    Rosenbaum R: Neuromuscular complications of connective tissue diseases. Muscle Nerve 2001, 24:154–169.CrossRefPubMedGoogle Scholar
  75. 75.
    Louthrenoo W, Ruttanaumpawan P, Aramrattana A, Sukitawut W: Cardiovascular autonomic nervous system dysfunction in patients with rheumatoid arthritis and systemic lupus erythematosus. QJM 1999, 92:97–102.CrossRefPubMedGoogle Scholar
  76. 76.
    Mori K, Iijima M, Sugiura M, et al.: Sjogren’s syndrome associated painful sensory neuropathy without sensory ataxia. J Neurol Neurosurg Psychiatry 2003, 74:1320–1322.CrossRefPubMedGoogle Scholar
  77. 77.
    Burns TM, Dyck PJ, Aksamit AJ, Dyck PJ: The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases. J Neurol Sci 2006, 244:77–87.CrossRefPubMedGoogle Scholar
  78. 78.
    Vital A, Lagueny A, Ferrer X, et al.: Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropathol 2008, 27:96–105.PubMedGoogle Scholar
  79. 79.
    Hoitsma E, Marziniak M, Faber CG, et al.: Small fibre neuropathy in sarcoidosis. Lancet 2002, 359:2085–2086.CrossRefPubMedGoogle Scholar
  80. 80.
    Hadjivassiliou M, Grunewald RA, Davies-Jones GA: Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry 2002, 72:560–563.CrossRefPubMedGoogle Scholar
  81. 81.
    Chin RL, Sander HW, Brannagan TH, et al.: Celiac neuropathy. Neurology 2003, 60:1581–1585.PubMedGoogle Scholar
  82. 82.
    Brannagan TH III, Hays AP, Chin SS, et al.: Small-fiber neuropathy/neuronopathy associated with celiac disease: skin biopsy findings. Arch Neurol 2005, 62:1574–1578.CrossRefPubMedGoogle Scholar
  83. 83.
    Gibbons CH, Freeman R: Autonomic neuropathy and coeliac disease. J Neurol Neurosurg Psychiatry 2005, 76:579–581.CrossRefPubMedGoogle Scholar
  84. 84.
    Cross AH, Golumbek PT: Neurologic manifestations of celiac disease: proven, or just a gut feeling? Neurology 2003, 60:1566–1568.CrossRefPubMedGoogle Scholar
  85. 85.
    Hadjivassiliou M, Davies-Jones GA, Sanders DS, Grunewald RA: Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 2003, 74:1221–1224.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Autonomic and Peripheral Nerve Laboratory, Department of NeurologyBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations